1. Home
  2. NMRA vs TSAT Comparison

NMRA vs TSAT Comparison

Compare NMRA & TSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NMRA
  • TSAT
  • Stock Information
  • Founded
  • NMRA 2019
  • TSAT 1969
  • Country
  • NMRA United States
  • TSAT Canada
  • Employees
  • NMRA N/A
  • TSAT N/A
  • Industry
  • NMRA
  • TSAT Metal Fabrications
  • Sector
  • NMRA
  • TSAT Industrials
  • Exchange
  • NMRA Nasdaq
  • TSAT Nasdaq
  • Market Cap
  • NMRA 287.6M
  • TSAT N/A
  • IPO Year
  • NMRA 2023
  • TSAT 1996
  • Fundamental
  • Price
  • NMRA $1.13
  • TSAT $20.89
  • Analyst Decision
  • NMRA Buy
  • TSAT Hold
  • Analyst Count
  • NMRA 8
  • TSAT 1
  • Target Price
  • NMRA $10.14
  • TSAT $9.00
  • AVG Volume (30 Days)
  • NMRA 1.3M
  • TSAT 103.5K
  • Earning Date
  • NMRA 03-03-2025
  • TSAT 05-09-2025
  • Dividend Yield
  • NMRA N/A
  • TSAT N/A
  • EPS Growth
  • NMRA N/A
  • TSAT N/A
  • EPS
  • NMRA N/A
  • TSAT 2.55
  • Revenue
  • NMRA N/A
  • TSAT $450,756,875.00
  • Revenue This Year
  • NMRA N/A
  • TSAT N/A
  • Revenue Next Year
  • NMRA N/A
  • TSAT N/A
  • P/E Ratio
  • NMRA N/A
  • TSAT $9.01
  • Revenue Growth
  • NMRA N/A
  • TSAT N/A
  • 52 Week Low
  • NMRA $1.13
  • TSAT $6.93
  • 52 Week High
  • NMRA $17.19
  • TSAT $25.38
  • Technical
  • Relative Strength Index (RSI)
  • NMRA 26.07
  • TSAT 52.65
  • Support Level
  • NMRA $1.13
  • TSAT $20.60
  • Resistance Level
  • NMRA $1.23
  • TSAT $25.38
  • Average True Range (ATR)
  • NMRA 0.12
  • TSAT 2.12
  • MACD
  • NMRA 0.05
  • TSAT 0.19
  • Stochastic Oscillator
  • NMRA 3.54
  • TSAT 54.09

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: